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Radical radiotherapy (RT) is a potentially curative treatment in non-small cell lung cancer
(NSCLC) and is delivered in conventional 2-Gy fractions, hypofractionated and ablative
stereotactic courses. No reliable, predictive biomarkers for the clinical events of local
control, appearance of distant metastases and development of toxicity have been
introduced in routine clinical practice. Such a test would enable the Radiotherapist
to tailor the clinical management of individual patients, considering their pre-treatment
characteristics, in order reduce the risk of recurrence or toxicity e.g., dose modification,
accelerated fractionation, hypofractionation, or concurrent systemic therapy. The aim of
this review was to map the published literature relating to investigations of the potential
predictive value of patient or treatment characteristics in radical RT for NSCLC. These
investigations should remain a research focus for disease control given the upward trends
in lung cancer incidence, and for the avoidance of toxicity, given the survivorship afforded
to the cohort of patients that do well with radical RT, or with the increasing range of
systemic agents following metastatic relapse. The conclusion of the presented analysis
is that there are no published, effective and validated predictive tools for estimation of
risk of local/distant recurrence or toxicity after radical RT for NSCLC. The authors have
identified an important space for future research in the field of lung cancer radiotherapy.
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INTRODUCTION
Radical radiotherapy (RT) is the term applied to describe a potentially curative dose of external
beam RT for patients with non-small cell lung cancer (NSCLC) (1). The key clinical outcomes
for patients undergoing radical RT are local tumor control, appearance of distant metastases
and the development of treatment toxicity. Improvements in RT planning and delivery in recent
years have resulted in its application to a broader range of patients, such as those with more
advanced local disease (2) and those with early stage disease (3). Improvements in staging and
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systemic therapy are leading to longer overall survival in patients
with locally advanced tumors (4). Despite these improvements
and the emergence and adaptation of the technology permitting
safe hypofractionated and ablative external beam radiotherapy,
no reliable, predictive biomarkers for local control, appearance
of distant metastases or development of toxicity have been
introduced. To our knowledge, this important area of clinically
unmet need has not been systematically reviewed. The purpose
of this study, which may serve as a foundation from which to
embark on dedicated research for radiotherapy researchers, is
to summarize the currently available literature on predictors of
the following three key clinical outcomes in treatment of NSCLC
with RT:
1. Local control;
2. Metastases free survival;
3. Treatment related toxicity.
All studies including univariate or multivariate analyses for the
effect of a patient or treatmeant characteristic on any of the 3
clinical outcomes of interest will be included in the analysis, or
any study seeking to apply a proposed model. The authors would
seek to establish a feasible line of investigation based on the
existing literature if possible.
METHODS
Literature Mapping
Literature mapping was performed to retrieve, collate and
map the variability found in the existing literature regarding
predictors of response to radical RT treatment of inoperable
NSCLC. Predictors of interest included were limited to:
• Prediction of which patients are likely to fail radical RT;
• Prediction of which patients are likely to benefit from
particular types of (chemo)RT.
To be useful for clinical decision-making, predictive factors
are defined as those covariates that are routinely available
at baseline before the start of treatment, such as patient
demographics, co-morbidities, disease characteristics, tumor
markers, or radiological findings.
Data Sources
On July 17, 2017, EMBASE and MEDLINE were searched via
Ovid SP and PubMed with no time/date, language, or document
type limitations. The search strategy documented in Box 1
was developed using Medical Subject Headings (MeSH) for
MEDLINE and Excerpta Medica Tree (EMTree) for EMBASE,
by a team of clinicians and medical information specialists with
database training.
Study Selection
Two reviewers independently screened titles and abstracts
of retrieved reports following deletion of obvious duplicates.
Full texts of studies that passed title/abstract screening were
then reviewed in detail to confirm eligibility. Randomized,
non-randomized studies and systematic reviews investigating
predictive factors or risk prediction models linked to response
rate, loco-regional control, metastatic relapse, or toxicity
were included where patients had stage I-III NSCLC and
underwent radical RT with or without sequential, concurrent or
adjuvant chemotherapy. All types of radical RT were included:
conventional 2-Gy fractions, hypofractionated, and ablative
stereotactic courses.
Manuscripts that were not available in full text, reported
in a language other than English, small in sample size (<50
patients), relating to outcomes not listed above or examining
predictive factors not available before beginning radical RT were
excluded. Studies including radiation and dosimetric parameters
as predictive factors were not selected for analysis, except where
they were part of a final risk prediction model. These and
other treatment variables such as fractionation and RT technique
would be better evaluated in a dedicated analysis of treatment
factors as predictive biomarkers, and thus are not presented in
this study.
One reviewer extracted data, and a sample (20%) of included
studies were double-checked and verified for accuracy to confirm
a satisfactory standard of extraction. Extraction included sample
size, study design and general characteristics, population and
tumor characteristics, radiotherapy and chemotherapy protocol,
predicted outcomes and statistically significant risk factors.
Adjusted estimates of association were extracted preferentially,
with lack of adjustment included in assessment of risk of bias.
To assess the risk of bias, screening questions were posed
about the suitability of the study design for testing of treatment
and risk factor interaction, risk of selection bias, important
confounding, and attrition bias. Studies were grouped into high,
moderate and low risk of bias with supporting evidence on the
data extraction form.
Risk factor association studies confined to a single treatment
or where treatment response was not compared between
intervention and control groups were not included as these
do not estimate risk of treatment response (5). If a factor
is associated with an outcome in both treated and untreated
patients, the factor cannot be considered as a predictor
of response to treatment and is best characterized as a
prognosticator of the course of illness with respect to that
particular outcome.
For risk prediction models we critically appraised the
studies according to the American Joint Committee on
Cancer Acceptance Criteria for Inclusion of Risk Models for
Individualized Prognosis in the Practice of Precision Medicine
(6).Models discriminating higher vs. lower risk patients were also
assessed for validity to predict a differential relative or absolute
benefit from treatment compared with an alternative option (5).
Data Coding
The following factors were recorded from the manuscripts
reviewed:
1) Funding
Industry funding was recorded where full or partial for-profit
funding was declared by the authors.
2) Study design
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BOX 1 | Search Strategies
EMBASE 1974 to 2017 Week 29
1. Exp Non Small Cell Lung Cancer/ OR (((Bronch∗ OR Lung OR Pulmon∗) adj (“Non Small Cell?” OR “Nonsmall Cell?”) adj (Cancer∗ OR Carcino∗)) OR ((“Non Small
Cell?” OR “Nonsmall Cell?”) adj (Bronchial OR Lung OR Pulmon∗) adj (Cancer∗ OR Carcino∗)) OR NSCLC∗).ti,ab.
2. Exp Radiotherapy/ OR (Radiotherap∗ OR (Radiation adj Therap∗)).ti,ab,fs.
3. Exp Prognosis/ OR Cohort Analysis/ OR Follow Up/ OR Incidence/ OR (Prognos∗ OR Predict∗ OR Outcome∗ OR Cohort OR “Follow Up” OR Followup∗ OR
Longitudinal OR Prospective OR Incidence).ti,ab.
4. Exp Survival/ OR Survival Analysis/ OR Kaplan Meier Method/ OR Survivor/ OR Cancer Survivor/ OR Exp Toxicity Testing/ OR Cancer Grading/ OR Cancer
Staging/ OR (Toxic∗ OR Local Tumo?r Control OR Surviv∗ OR “Kaplan Meier” OR Model∗ OR ((Gleason OR Cancer OR Tumo?r OR TNM) adj (Stag∗ OR Grad∗
OR Scor∗))).ti,ab. OR (Toxicity).fs.
5. 1 AND 2 AND 3 AND 4
6. Exp Animals/ OR Exp Invertebrate/ OR Animal Experiment/ OR Animal Model/ OR Animal Tissue/ OR Animal Cell/ OR Nonhuman/
7. Human/ OR Normal Human/ OR Human Cell/
8. 6 AND 7
9. 6 NOT 8
10. 5 NOT 9
11. Limit 10 to EMBASE
MEDLINE
1. “Carcinoma, Non-Small-Cell Lung”/ OR (((Bronch∗ OR Lung OR Pulmon∗) adj (“Non Small Cell?” OR “Nonsmall Cell?”) adj (Cancer∗ OR Carcino∗)) OR ((“Non
Small Cell?” OR “Nonsmall Cell?”) adj (Bronchial OR Lung OR Pulmon∗) adj (Cancer∗ OR Carcino∗)) OR NSCLC∗).ti,ab.
2. Exp Radiotherapy/ OR (Radiotherap∗ OR (Radiation adj Therap∗)).ti,ab,fs.
3. Prognosis/ OR Exp Cohort Studies/ OR Follow-Up Studies/ OR Incidence/ OR (Prognos∗ OR Predict∗ OR Outcome∗ OR Cohort OR “Follow Up” OR Followup∗
OR Longitudinal OR Prospective OR Incidence).ti,ab.
4. Survival/ OR Survivors/ OR Exp Survival Analysis/ OR Survival Rate/ OR Disease-Free Survival/ OR Exp Toxicity Tests/ OR Neoplasm Grading/ OR Neoplasm
Staging/ OR (Toxic∗ OR Local Tumo?r Control OR Surviv∗ OR “Kaplan Meier” OR Model∗ OR ((Gleason OR Cancer OR Tumo?r OR TNM) adj (Stag∗ OR Grad∗
OR Scor∗))).ti,ab. OR (Toxicity).fs.
5. 1 AND 2 AND 3 AND 4
6. 5 NOT (Animals NOT (Humans and Animals)).sh.
7. Limit 6 to MEDLINE
PubMed
(((Bronchial[tiab] OR Lung[tiab] OR Pulmon∗[tiab]) AND (“Non Small Cell”[tiab] OR “Nonsmall Cell”[tiab]) AND (Cancer∗[tiab] OR Carcino∗[tiab])) OR NSCLC∗[tiab])
AND (Radiotherap∗[tiab] OR (Radiation[tiab] AND Therap∗[tiab])) AND (Prognos∗[tiab] OR Predict∗[tiab] OR Outcome∗[tiab] OR Cohort[tiab] OR “Follow Up”[tiab] OR
Followup∗[tiab] OR Longitudinal[tiab] OR Prospective[tiab] OR Incidence[tiab]) AND (Toxic∗[tiab] OR “lOCAL Tumor Control”[tiab] OR “Local Tumour Control”[tiab]
OR Surviv∗[tiab] OR “Kaplan Meier”[tiab] OR Model∗[tiab] OR ((Gleason[tiab] OR Cancer[tiab] OR Tumor[tiab] OR Tumour[tiab] OR TNM[tiab]) AND (Stag∗[tiab] OR
Grad∗[tiab] OR Scor∗[tiab]))) NOT MEDLINE[sb]
Included studies were categorized as follows:
Predictive Factor Research (Univariate Analysis)
Patient, tumor, treatment, or biomarker factor and the
association with a given outcome.
Predictive Model Research (Multivariate Analysis)
Studies may be model derivation studies, model validation
(internal or external) studies, or both. Those given alternative
titles such as prediction index or rule were also included.
Predictive Impact Studies
Studies evaluate the effect of using a predictive model on patient
outcomes. Such studies require a parallel control group of
standard care or involve a time-series type design. Predictive
impact studies evaluate the impact of a model on decision-
making and patient outcomes. Methodological evaluation of
these impact studies is similar to evaluation of effectiveness of
drugs/devices/procedures.
Study design categorization was based both on the conduct
of the study and the analytic approach for risk prediction. For
example, a comparative studymay have analyze the outcome data
pooled from all interventional groups using a multi/univariate
regression analysis with treatment as a covariate, but because
estimate of differential treatment effect was not the dependent
factor for risk prediction, the study was characterized as non-
comparative.
3) Predictive factors
Considerable heterogeneity was discovered in reported risk
factors across studies. The following variables were extracted:
Chemotherapy: concurrent vs. sequential or no
chemotherapy; specific regimens vs. other regimens
Comorbidity: classification scores, interstitial lung disease,
COPD, vascular embolism, necrotic tumors
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Contouring: gross tumor volume
Fractionation: hyperfractionation, hypofractionation,
conventional fractionation, inter-fraction interval
Imaging: coarseness, contrast, busyness, apparent diffusion
coefficient
Lung function: transfer factor, total lung capacity, diffusing
capacity
Medications: β-blockers, ACE inhibitors
Molecular markers: single nucleotide polymorphisms and
tumor markers
Performance status: ECOG or KPS
PET data: maximum standard uptake value; retention index,
metabolic tumor volume, tumor growth rate, total lesion
glycolysis
RT technique: 2D conventional, 3D-CT, IMRT, Arc therapy,
stereotactic
Stage: clinical, tumor dimensions, PET-CT findings, final
TNM stage
Trace elements (hair): Au and Cu
4) Fractionation
Conventional RT
Total dose 50–55Gy, in approx. 20 fractions or approx. 2
Gy/fraction
Conventional RT, dose intensified
Total dose >55Gy when given in 20 fractions or total dose
>66Gy when reported as 2G per fraction
Hypofractionation
Investigator defined. Employs fewer total fractions but
increased dose per fraction.
Hyperfractionation
Investigator defined. RT is givenmore than once per day. Total
RT dose may be lower or higher than conventional schedules.
RESULTS
The results section has been divided into characteristics
of studies and the patients included, summarized
publications relating to toxicity, summarized
publications relating to local/distant disease control, and
summarized publications relating to predictive model
validation.
FIGURE 1 | PRISMA flow diagram.
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Study Characteristics
The PRISMA flow diagram in Figure 1 illustrates the flow of
7320 reports retrieved in literature searches as they were screened
for eligibility. A total of 259 reports were finally included (see
Appendix A in Supplementary Material). Excluded studies were
categorized by exclusion criterion listed in Box 2 (see Appendix
B in Supplementary Material). Approximately 63% of included
reports were published in the period 2010–2016 (see Appendix C
in Supplementary Material, Figure 1).
The majority of reports described reports of prognostic
factors as opposed to investigations of predictors of outcome.
Most studies were of non-comparative, single-arm design,
precluding assessment of prediction of differential response to
radical RT. The few comparative studies that compared one
technique, fractionation, dose, or chemoradiotherapy protocol
with another, did not analyse the data in a manner that would
permit investigation of predictors of relative treatment effect as
conceptualized in the Introduction.
Ten risk predictionmodels were also identified in the included
body of evidence. Several of these were also categorized as
prognostic factor research. Only one prognostic model was
externally validated and further refined and no model was
validated for predicting response to therapy.
Hingorani et al. suggest that validation of models
predictive of response to treatment includes estimation of
individual risk of patients, categorizing patients into higher
and lower risk groups, and establishing that relative or
absolute benefits from a treatment are distinctly different
for higher and lower risk patients (5). As such, all model
development studies and the vast majority of predictive
BOX 2 | Reasons for Exclusion of reports.
(1) Sample size < 50, N = 8
(2) Population was not predominantly (>95% of population) stage IA, IB, IIA, IIB, IIIA, and/or IIIB NSCLC or an analyzed subgroup of these stages, N = 72
(3) Treatment was not radical RT – patients had surgery before radiotherapy, N = 36
(4) Did not investigate risk factor(s) and radical RT association, N = 5
(5) Did not clinical impact (effectiveness and harms) of response to radical RT risk prediction guided patient management, N = 1
(6) Language other than English, N = 45
(7) Record is a non-systematic review, letter, editorial, or case-report, N = 19
(8) Investigation is about average risk/incidence/odds of specific outcomes following radical RT (i.e., fundamental prognosis research) but not about predictive
factor risk assessment, N = 1
(9) Predicted outcome is not a pre-specified outcome, N = 77
(10) Reports excluded because none of the risk factors evaluated are factors that were measured at or before the start of radical RT, N = 3
(11) Reports excluded because evaluated radical RT dose (but not the modality of radical RT) as the only risk factor for response to treatment, N = 16
(12) Model development methods paper using radiotherapy for NSCLC as an example; results not intended as formal clinical findings, N = 2
(13) Unclear record, N = 30
TABLE 1 | Mapping of study population and tumor characteristics (n = 259).
Item Variables N % Item Variables N %
Tumor stage Tumor histology
I only 40 15 Squamous cell CA 2 1
III only 100 39 Non-squamous cell CA 7 3
Stage I-III (mixed) 64 25 Mixed squamous and non-squamous cell CA 209 81
Other combinations (stage I &III, I & II, and
II & III)
55 21 NR 41 16
Staging
PET-staged 49 19 Age
PET or CT-staged 20 8 Predominantly or exclusively elderly (>65 y) 12 5
Non-PET staged 59 23 Non-elderly only (≤65 y) 0 0
NR 131 51 Mixed elderly and non-elderly ages 233 90
Performancestatus NR 14 5
Predominantly (≥80% of sample) ≤2
(ECOG) OR ≥ 60 (KPS)
164 63
Unclear or other distribution 46 18
NR 49 19
CA, carcinoma; N, number of study reports; NR, not reported; PET, positron emission tomography; CT, computerized tomography; NR, not reported; ECOG, Eastern Cooperative
Oncology Group; KPS, Karnofsky performance status.
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factor research identified were considered to be of poor
quality with respect to the objective of predicting response to
radical RT.
The 255 included studies (comprising 259 reports) were
based on data from 71,993 patients. However, the true number
of included patients is likely to be slightly lower due to the
inclusion of some companion reports that were not identified
as such. Single-center studies comprised 66% of the included
manuscripts, multi-center comprised 22%, and the remainder
did not report. Industry sponsorship was documented for
8% included studies, non-profit organization sponsorship for
39% and 53% studies did not include these details. Most
studies (95%) were conducted in North America, Europe or
Asia.
TABLE 2 | Mapping of statistically significant predictors of radiotherapy toxicity.
Outcome (N reports) Patient factors % Tumor factors % Treatment factors % % of reports with no
significant predictor
Oesophagitis (37) 65
Age 5 Stage 3 Chemotherapy 24
Gender 3 Fractionation 3
Performance status 3 RT technique 8
Race 5
Molecular marker (SNP) 5
Oesophageal stricture (1) 100
Composite oesophageal
toxicity (18)
61
Gender 6 Stage 11 Chemotherapy 28
Symptoms 6
Molecular marker (TGF-β) 6
Weight loss 17
Radiation pneumonitis (58) 64
Age 9 PET data 2 Chemotherapy 10
Comorbidity 3 PTV 5 RT technique 3
Gender 2 Stage 5 RT fractionation 2
Lung function 7 Tumor site 3
Lung volume 2
Medications 2
Performance status 7
Smoking 9
Molecular markers (APEX1,
AT1, Protein, SNP, TGF-β,
TNF, VEGF, XRCC1,
XRCC3)
10
Lung fibrosis (2) 100
Composite lung toxicity (27) 70
Age 15 Histology (large cell vs.
adenocarcinoma)
4 Chemotherapy 7
Comorbidity 11 Fractionation (N of fractions) 4
Gender 4 Stage 11 Treatment center 4
Lung function 4 Tumor site 7 RT Technique 7
Performance status 4
Race 4
Weight loss 7
Composite acute toxicities
(1)
0
Tumor site 100
Death due to RT toxicity (4) 50
Tumor site 50
Identical study reports may be counted for more than one predictor therefore total percentage may not be equal to 100.
AT, angiotensin receptor; N, number of; PTV, planning target volume; RT, radiotherapy; SNP, single-nucleotide polymorphism; TGF-β, transforming growth factor beta; TNF, tumor
necrosis factor; VEGF, vascular endothelial growth factor; vs, versus.
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Randomized controlled trials comprised only 8% included
studies and a further 3% included studies were comparative
but not randomized, but the majority (90%) of identified
studies were non-comparative. Two systematic reviews were
identified as meeting the inclusion criteria. Risk of bias was
deemed high in 65% randomized controlled trials, 100% of non-
randomized comparative studies and 100% non-comparative
studies.
TABLE 3 | Mapping of statistically significant predictors of local or distant tumor control.
Outcome (N) Patient factors % Tumor factors % Treatment factors % % of reports with no
significant predictor
LOCAL CONTROL (outcomes: disease free survival, disease progression, failure free survival, local failure, local progression free survival, local or
disease recurrence, nodal failure, non-local relapse free survival, primary tumor control, time to progression, tumor growth, or tumor shrinkage)
181 49
Age 6 Date (staging after PET scan
introduction)
<1 Booster field size <1
Blood marker
(neutrophil/lymphocyte ratio)
<1 Histology (SCC or
lymphovascular invasion)
7 Chemotherapy 12
Gender 9 Imaging (texture) 2 Contouring 2
Lung function <1 PET data 8 Field size <1
Medication <1 PTV <1 Fractionation 3
Molecular markers (e.g., AI,
Bcl-2, COX2, EGFR, FasL,
FGF-2, HER-2, MMP-2,
p53, SPARC expression,
Rb, trace elements, VEGF,
etc.)
7 Stage 34 RT technique 5
Performance status 17 Tissue(clinical vs.
pathological diagnosis)
<1
Smoking 2 Total tumor volume 2
Symptoms 1 Tumor site 3
Weight loss 4
DISTANT CONTROL (outcomes: metastatic disease-free survival, distant metastasis, or distant failure)
72 46
Age 6 Histology (SCC,
lymphovascular invasion, or
tumor grade)
11 Chemotherapy 3
Blood marker
(platelet-to-lymphocyte
ratio)
1 PET data 8 Contouring 1
Comorbidity 4 Stage 24 Fractionation 4
Gender 8 Total tumor volume 1 RT Technique 1
Medication 1 Tumor site 4
Molecular markers (e.g.,
SNP, apoptotic index, index
based on CRP, albumin,
etc.)
7
Performance status 15
Weight loss 6
BRAIN METASTASIS
8 50
Age 25 Histology (SCC or tumor
grade)
38 Chemo 13
Molecular marker
(neuron-specific enolase or
CA125)
25 Tumor marker 13
Performance status 13
Identical study reports may be counted for more than one predictor therefore total percentage may not be equal to 100.
AI, Apoptotic index; EGFR, epidermal growth factor receptor; FGF-2, fibroblast growth factor-2; HER-2, human epidermal growth factor receptor-2; MMP-2, matrix metalloproteinase;
Rb, retinoblastoma protein; VEGF, vascular endothelial growth factor; SCC, squamous cell carcinoma; PTV, planning target volume; RT, radiotherapy.
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A majority of studies included patients with stage III
disease (exclusively, or with stage I/II) of a range of ages
and tumor histology (Table 1). Performance status was not
reported in 19% of reports, while over 60% of studies
included patients a performance status of ECOG ≤ 2 or
KPS ≥ 60.
Radical RT techniques commonly described in the studies
included 3D-conformal, IMRT, and stereotactic ablative
radiotherapy (see Appendix C in Supplementary Material,
Table 1). Fractionation varied widely between the included
studies with no clearly preferred schedule. Radical RT was
reported to have been administered without chemotherapy in
31% of included reports, concurrently with chemotherapy
in 13% and sequentially in 3% (see Appendix C in
Supplementary Material, Table 2).
Predictors of Toxicity With Radical RT
Radical RT toxicity outcomes were reported in 43% of studies
(Table 2). Of the reports demonstrating a positive association
between a factor and acute oesophageal or lung toxicity
outcomes, no marker was found to have a consistent prognostic
value, reflecting variability in the design of studies, findings, or
both. Across studies contributing data for any one of the toxicity
outcomes of interest, chemotherapy was the most commonly
reported statistically significant risk factor (20% of 112 reports).
Age, gender, performance status, tumor stage, fractionation,
radiotherapy technique and molecular markers were found to be
significant risk factors ≤15% of reports investigating a toxicity
outcome.
Predictors of Local/Distant Control With
Radical RT
One hundred and eighty-one reports investigated the association
between a risk factor and local tumor control, defined
inconsistently in the included reports (Table 3). Almost 50% of
these studies found no statistically significant association. Of the
reported risk factors that were significantly associated with local
control, most commonwere tumor stage, performance status and
chemotherapy administration.
Distant tumor control was investigated in 72 reports, with
almost half reporting no significant association with any
risk factor (Table 3). Of the reported risk factors that were
significantly associated with distant control, most common were
tumor stage, performance status, and tumor histology.
Studies were generally not designed to investigate predictors
of response to radical RT. All risk factors for which a
statistically significant association was found were prognostic
factors predicting the risk of outcomes following (chemo)RT.
Whether these factors could also guide treatment selection
remains to be established.
Prognostic Models Predicting Treatment
Response
Included reports were model development or validation studies
in 10 of 259 cases. Sample size ranged from 54 to 836 patients.
No model was validated for prediction of response to treatment
and therefore all models were considered inappropriate for
guiding patient selection for specific treatments. A vast range of
predicted outcomes were noted in these studies (see Appendix D
in Supplementary Material).
DISCUSSION
Prognostic research predicts the course of illness, not response to
therapy. Prediction of response to treatment guides appropriate
treatment selection based on risk characteristics shared by
subgroups of patients. When the relative treatment effect is the
approximately the same for all subgroups of patients, treatment
decisions are best guided by patients’ individual baseline risk for
outcomes. Baseline risk is evaluated in prognostic risk factor and
prognostic model research, which are distinct from predictive
factor research investigating differential treatment response.
Patient groups with a higher baseline risk will have greater
absolute benefits than patients with a lower baseline risk.
This mapping exercise highlights a clear paucity of predictive
factor research, an important component of stratified medicine,
in the setting of radical RT for NSCLC (5). Parameters
that have been considered as predictive biomarkers in the
literature analyzed include patient demographics, initial
staging and radiomic and dosimetric correlates. This limited
available published evidence was found to be at high risk
of confounding from various biases (see Appendix D in
Supplementary Material) however, meaning these signals must
be interpreted with caution. It may be that they provide a
framework with which to begin new workstreams of radical
RT research. The evidence base in NSCLC patients undergoing
radical RT is of the prognostic type predominantly. The
presented results are in keeping with the previous observation
that most risk estimation is of a prognostic type, rather than
predictive of response to therapy (5, 7).
The presented review exposes the gross uncoupling of
radiation and medical oncology in the implementation of
biomarker-informed clinical decision making. An array of
technical overtures have reformed radiation oncology in recent
decades, leading to gains in tumor control and treatment
toxicity predominantly through improved accuracy (8). However
systemic therapy for lung cancer has been revolutionized for the
subsets of patients with an EGFR mutation, ALK rearrangement
or PD-L1 positivity by targeted agents which are initiated in
appropriate clinical scenarios and based on widely available
predictive biomarkers (9). There is increasing appreciation
amongst academic radiation oncologists and clinician scientists
that such novel biology-based discovery and translation can
only result from an intense research focus in radiotherapy.
New collaborative groups with this ethos are currently striving
to address the illustrated dearth of predictive biomarkers in
radiotherapy (10).
It is important for patients with NSCLC that more
personalized radiotherapy approaches are developed rapidly,
given the disappointing outcomes experienced on the whole in
this difficult disease. Future research on truly predictive factors
needs to focus in two directions. Firstly, more precise markers of
individual response and risk need to be developed. These might
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include molecular biomarkers for radiosensitivity in both tumor
and patient, immune host markers and fuller imaging analysis
such as radiomics. In parallel, trial design must be adapted so
that individual factors can be assessed for their relationship with a
differential trial arm outcome for assessment of predictive value.
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